| Systematic (IUPAC) name | |
|---|---|
| N-(4-Chlorobenzoyl)-3-(2-oxo-1,2-dihydroquinolin-4-yl)alanine | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 90098-04-7 |
| ATC code | None |
| PubChem | CID 5042 |
| IUPHAR ligand | 871 |
| ChemSpider | 4866 |
| UNII | LR583V32ZR |
| KEGG | D01121 |
| ChEMBL | CHEMBL1697771 |
| Chemical data | |
| Formula | C19H15ClN2O4 |
| Mol. mass | 370.786 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Rebamipide, an amino acid derivative of 2(1H)-quinolinone, is used for mucosal protection, healing of gastroduodenal ulcers, and treatment of gastritis. It works by enhancing mucosal defense, scavenging free radicals, and temporarily activating genes encoding cyclooxygenase-2.
Studies have shown that Rebamipide can fight the damaging effects of NSAIDs on the GIT Mucosa, and more recently, the small intestine.
It has also been used for the treatment of Behçet's disease.
It was shown to successfully treat pouchitis in a single-N study after first line therapies for the condition were unsuccessful (http://www.wjgnet.com/1007-9327/12/656.pdf).
Some studies have shown effectiveness in presbyacusis (age-related hearing loss).
|
||||||||||||||||||||||
| This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)